Nabriva Therapeutics plc (NBRVF)

Market Cap	3.00 -100.0%
Revenue (ttm)	29.56M -16.4%
Net Income	-55.05M
EPS	-17.90
Shares Out	3.23M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,384
Average Volume	0
Open	0.0001
Previous Close	n/a
Day's Range	0.0001 - 0.0001
52-Week Range	0.000001 - 0.0002
Beta	1.64
RSI	1.39
Earnings Date	n/a

About Nabriva Therapeutics

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for oral and IV administration. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infect...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2005
• Country: United States
• Stock Exchange: OTCMKTS
• Ticker Symbol: NBRVF